Los Angeles Capital Management LLC purchased a new position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 35,721 shares of the company's stock, valued at approximately $379,000. Los Angeles Capital Management LLC owned 0.06% of Immunome as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the company. Janus Henderson Group PLC lifted its position in shares of Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company's stock worth $50,971,000 after purchasing an additional 324,614 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Immunome by 217.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company's stock worth $6,469,000 after acquiring an additional 302,916 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock worth $10,684,000 after acquiring an additional 237,497 shares during the period. Geode Capital Management LLC raised its stake in shares of Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company's stock valued at $17,657,000 after acquiring an additional 144,557 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Immunome by 22.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company's stock worth $6,881,000 after purchasing an additional 85,580 shares in the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.
Immunome Stock Up 2.1 %
IMNM traded up $0.19 on Friday, reaching $9.41. The company had a trading volume of 240,340 shares, compared to its average volume of 917,847. Immunome, Inc. has a 1 year low of $8.55 and a 1 year high of $28.19. The stock has a market capitalization of $750.94 million, a PE ratio of -1.16 and a beta of 1.93. The stock has a 50-day moving average price of $10.18 and a 200-day moving average price of $12.06.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on IMNM. Piper Sandler decreased their price objective on Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Stephens initiated coverage on shares of Immunome in a report on Friday, November 8th. They issued an "overweight" rating and a $30.00 price objective on the stock. Finally, Wedbush reiterated an "outperform" rating and set a $33.00 target price on shares of Immunome in a research note on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $28.60.
View Our Latest Report on Immunome
Insider Activity
In other Immunome news, CEO Clay B. Siegall bought 150,000 shares of the stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the transaction, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.60% of the company's stock.
Immunome Profile
(
Free Report)
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Featured Stories
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
